InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.17
(
0.23%
)
Bitcoin
69,039.27
(
0.77%
)
Post# of 251941
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 210794

Tuesday, 04/25/2017 11:02:45 AM

Tuesday, April 25, 2017 11:02:45 AM

Post# of 251941
>>JNJ/ACHN—3-DAA* HCV regimen has good-news/bad-news—mostly bad

So here's my question: Is it not plausible that the bulk of the yet untreated patients in the US fall in the non-cirrhotic GT1 category? My assumption is that the "tough" patients have been treated first and that the bulk of the residue constitute "easy" patients.

Thoughts? Will the market demand a pan-genotype treatment, or will patients still be genotyped and segregated into categories to be treated accordingly? If the latter, I could see a role for a 6 week treatment for the easy patients. So will JNJ take this forward?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up